Robert E. Hoffman - 01 Jun 2023 Form 4 Insider Report for Kintara Therapeutics, Inc. (HURA)

Reporting relationship: President, CEO, and CFO, Director
Issuer ticker: HURA
Reported as of: 01 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2023, 16:05:29 UTC
Prior SEC filing: 03 Aug 2022
Next SEC filing: 01 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Robert E. Hoffman

Key filing fact

Robert E. Hoffman filed Form 4 for Kintara Therapeutics, Inc. (HURA) on 02 Jun 2023.

Key facts

This page summarizes Robert E. Hoffman's Form 4 filing for Kintara Therapeutics, Inc. (HURA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2023, 16:05.

Change

Previous filing in this sequence was filed on 03 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KTRA transaction

Common Stock, par value $0.001 per share

Award

Transaction value: $0
Shares: +59,800
Change %: +657%
Price: $0.000000
Shares after: 68,902
Date: 01 Jun 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person was granted 59,800 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in full on June 1, 2024.